Fennec Pharmaceuticals (FENC) Common Equity (2010 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Common Equity came in at $35.5 million in Q4 2025, up 704.09% YoY from $4.4 million in Q4 2024, and up 889.67% on a QoQ basis from -$4.5 million in Q3 2025.
Fennec Pharmaceuticals (FENC) Common Equity (2010 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 16 years of Common Equity data on file, last reported at $35.5 million in Q4 2025.
- Quarterly Common Equity rose 704.09% year-over-year to $35.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.5 million (up 704.09% YoY) and the FY2025 annual result came in at $35.5 million, up 704.09% from the prior year.
- Common Equity rose to $35.5 million in Q4 2025, from -$4.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $35.5 million in Q4 2025 to a low of -$11.6 million in Q4 2023.
- A 5-year average of $3.6 million and a median of -$2.0 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity tumbled 475.84% — and 2025, when it surged 704.09%.
- Tracing FENC's Common Equity over 5 years: stood at $15.8 million in 2021, then tumbled by 116.29% to -$2.6 million in 2022, then sank by 352.39% to -$11.6 million in 2023, then jumped by 49.48% to -$5.9 million in 2024, then surged by 704.09% to $35.5 million in 2025.
- The last three Common Equity figures came in at $35.5 million (Q4 2025), -$4.5 million (Q3 2025), and -$7.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn | 42.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.44 Mn |
| Dec 31, 2025 | 35.47 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Jun 30, 2025 | -7.46 Mn |
| Mar 31, 2025 | -5.88 Mn |
| Dec 31, 2024 | -5.87 Mn |
| Sep 30, 2024 | -5.17 Mn |
| Jun 30, 2024 | -1.36 Mn |
| Mar 31, 2024 | 3.01 Mn |
| Dec 31, 2023 | -11.62 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -9.73 Mn |
| Mar 31, 2023 | -7.34 Mn |
| Dec 31, 2022 | -2.57 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 8.54 Mn |
| Mar 31, 2022 | 12.52 Mn |
| Dec 31, 2021 | 15.77 Mn |
| Sep 30, 2021 | 19.01 Mn |
| Jun 30, 2021 | 22.28 Mn |